Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.

ABSTRACT:

Background

Second generation drug-eluting stents were developed to improve the safety and efficacy of first generation stents. So far, limited long term randomized data exist comparing the second generation everolimus-eluting stents (EES) with first generation sirolimus-eluting stents (SES).

Methods

A prospective, open-label, randomized, single center trial comparing EES and SES in all-comer patients. The primary endpoint was a composite of cardiac mortality, myocardial infarction and target vessel revascularization. Secondary endpoints included individual components of the composite, along with target lesion revascularization and stent thrombosis.

Results

In total, 977 patients were randomized, of which 498 patients to EES and 479 to SES. Average age was 65.2 ± 11.2

SUBMITTER: Velders MA 

PROVIDER: S-EPMC3670908 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature